ArticleJournal of medical microbiology2025
The lingering legacy of one letter in antimicrobial susceptibility testing.
Article in Journal of medical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For decades, the 'Intermediate' (I) category in antimicrobial susceptibility testing was frequently misinterpreted as indicative of therapeutic failure, rather than an opportunity for dose optimization. This misunderstanding shaped prescribing behaviour, antimicrobial trial design and guideline development. The 2019 European Committee on Antimicrobial Susceptibility Testing redefinition of the 'I' category as 'Susceptible, Increased Exposure' (SIE) highlighted the potential for treatment efficacy through dose adjustment, challenging entrenched prescribing behaviours and exposing limitations in historical trials, guidelines and surveillance practices. Antimicrobial stewardship that employs SIE-based strategies can preserve narrower-spectrum agents. However, the misapplication of 'I' can promote unnecessary broad-spectrum antimicrobial prescribing. Surveillance systems, clinical decision support and antimicrobial stewardship should be continuously updated to reflect current pharmacological principles and thereby enhance patient care outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.